Therapeutic Targeting of the Tumor Microenvironment
- PMID: 33811125
- DOI: 10.1158/2159-8290.CD-20-1808
Therapeutic Targeting of the Tumor Microenvironment
Abstract
Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a promising approach for cancer treatment in recent years due to the critical roles of the TME in regulating tumor progression and modulating response to standard-of-care therapies. Here, we summarize the current knowledge regarding the most advanced TME-directed therapies, which have either been clinically approved or are currently being evaluated in trials, including immunotherapies, antiangiogenic drugs, and treatments directed against cancer-associated fibroblasts and the extracellular matrix. We also discuss some of the challenges associated with TME therapies, and future perspectives in this evolving field. SIGNIFICANCE: This review provides a comprehensive analysis of the current therapies targeting the TME, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.
©2021 American Association for Cancer Research.
Similar articles
-
Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.OMICS. 2020 Apr;24(4):175-179. doi: 10.1089/omi.2020.0019. Epub 2020 Mar 13. OMICS. 2020. PMID: 32176591 Review.
-
Targeting the tumor microenvironment: Potential strategy for cancer therapeutics.Biochim Biophys Acta Mol Basis Dis. 2023 Aug;1869(6):166746. doi: 10.1016/j.bbadis.2023.166746. Epub 2023 May 7. Biochim Biophys Acta Mol Basis Dis. 2023. PMID: 37160171 Review.
-
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Nat Rev Clin Oncol. 2018 May;15(5):325-340. doi: 10.1038/nrclinonc.2018.29. Epub 2018 Mar 6. Nat Rev Clin Oncol. 2018. PMID: 29508855 Free PMC article. Review.
-
The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.Cell Oncol (Dordr). 2021 Dec;44(6):1209-1229. doi: 10.1007/s13402-021-00634-9. Epub 2021 Sep 16. Cell Oncol (Dordr). 2021. PMID: 34528143 Review.
-
Unlocking the potential of the tumor microenvironment for cancer therapy.Pathol Res Pract. 2023 Nov;251:154846. doi: 10.1016/j.prp.2023.154846. Epub 2023 Oct 4. Pathol Res Pract. 2023. PMID: 37837860 Review.
Cited by
-
SUGT1 regulates the progression of ovarian cancer through the AKT/PI3K/mTOR signaling pathway.Transl Oncol. 2024 Nov;49:102088. doi: 10.1016/j.tranon.2024.102088. Epub 2024 Aug 20. Transl Oncol. 2024. PMID: 39167956 Free PMC article.
-
The epiphany derived from T-cell-inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses.Front Genet. 2022 Aug 11;13:974416. doi: 10.3389/fgene.2022.974416. eCollection 2022. Front Genet. 2022. PMID: 36035168 Free PMC article.
-
Characterization and verification of CAF-relevant prognostic gene signature to aid therapy in bladder cancer.Heliyon. 2024 Jan 11;10(3):e23873. doi: 10.1016/j.heliyon.2023.e23873. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38317915 Free PMC article.
-
Risk Predictive Model Based on Three DDR-Related Genes for Predicting Prognosis, Therapeutic Sensitivity, and Tumor Microenvironment in Hepatocellular Carcinoma.J Oncol. 2022 Sep 30;2022:4869732. doi: 10.1155/2022/4869732. eCollection 2022. J Oncol. 2022. PMID: 36213834 Free PMC article.
-
Integrated single-cell and transcriptome sequencing analyses determines a chromatin regulator-based signature for evaluating prognosis in lung adenocarcinoma.Front Oncol. 2022 Oct 17;12:1031728. doi: 10.3389/fonc.2022.1031728. eCollection 2022. Front Oncol. 2022. PMID: 36324565 Free PMC article.
References
-
- Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346–54.
-
- Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37.
-
- Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005;7:513–20.
-
- Salmon H, Remark R, Gnjatic S, Merad M. Host tissue determinants of tumour immunity. Nat Rev Cancer. 2019;19:215–27.
-
- Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25:198–213.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical